Fact-checked by Grok 2 weeks ago

Helenalin

Helenalin is a , a primarily isolated from the flowers of and other species in the family, such as plants. With the molecular C15H18O4 ( 262.30 g/mol; 6754-13-8), it features reactive exomethylene and α,β-unsaturated carbonyl groups that enable its biological interactions. Known for its potent effects, helenalin has been used in traditional folk medicine for centuries to treat minor injuries and , though its therapeutic potential is constrained by . The compound's primary mechanism of action involves selective inhibition of the transcription factor NF-κB, achieved by direct alkylation of the p65 subunit through Michael-type addition to its cysteine sulfhydryl groups. This modification prevents NF-κB from binding to DNA without affecting IκB degradation or nuclear translocation, leading to downregulation of proinflammatory cytokines like IL-1, IL-6, and TNF-α. In addition to anti-inflammatory properties, helenalin demonstrates in vitro antineoplastic activity by inducing apoptosis and inhibiting telomerase, as well as antitrypanosomal effects with IC50 values as low as 0.05 μM against Trypanosoma species. The total sesquiterpene lactone content in Arnica montana flowers, including helenalin and its derivatives, typically ranges from 0.4% to 0.6%, as standardized by the European Pharmacopoeia, and helenalin concentrations up to 3% dry weight in Helenium species. However, its bitterness and toxicity—responsible for the poisonous nature of Arnica—limit safe use, with oral LD50 values of 85–150 mg/kg in mammals and potential for allergic reactions in humans. Ongoing research, including 2023 studies on its anti-cancer potential in breast cancer cell lines, explores synthetic analogs to harness its benefits while mitigating these risks for applications in anti-inflammatory and anticancer therapies.

Chemical Properties

Structure

Helenalin is a pseudoguaianolide characterized by a fused bicyclic consisting of a seven-membered ring and a five-membered ring, along with an α-methylene-γ-lactone moiety and a cyclopentenone . Its molecular formula is C_{15}H_{18}O_4, with a of 262.305 g·mol^{-1}. The IUPAC name for helenalin is (3aS,4S,4aR,7aR,8R,9aR)-4-hydroxy-4a,8-dimethyl-3-methylidene-3,3a,4,4a,7a,8,9,9a-octahydroazuleno[6,5-b]furan-2,5-dione, reflecting its specific at six chiral centers (positions 3a, 4, 4a, 7a, 8, and 9a). Helenalin exists in polymorphic forms that differ primarily in their hydrogen-bonding patterns and molecular packing arrangements within the .

Reactivity

Helenalin exhibits significant chemical reactivity primarily due to its electrophilic functional groups, which enable interactions with biological nucleophiles. The molecule contains an α-methylene-γ-butyrolactone moiety and an α,β-unsaturated cyclopentenone group, both serving as acceptors that facilitate conjugate additions. The reactivity of helenalin is dominated by the addition , wherein these electrophilic sites undergo 1,4-addition with thiol-containing nucleophiles, such as residues in proteins or (GSH). This process forms stable covalent adducts, with the addition to the α-methylene-γ-butyrolactone being irreversible, while the cyclopentenone addition is reversible under physiological conditions. The general reaction for this Michael addition can be represented as: \text{Helenalin} + \text{R-SH} \rightarrow \text{Helenalin-S-R (adduct)} where the exocyclic methylene of the or the β-carbon of the enone accepts the in a 1,4-fashion, leading to saturation of the double bond and thioether formation. Helenalin's , modulated by its rigid molecular conformation and lack of polar substituents, enhances its ability to permeate membranes, thereby facilitating access to intracellular targets for these reactive interactions.

Derivatives

Helenalin derivatives include both naturally occurring and semi-synthetic compounds that modify its pseudoguaianolide , primarily through of bonds or conjugation with other molecules. A key natural derivative is dihydrohelenalin (also known as 11α,13-dihydrohelenalin), which features saturation of the exocyclic at positions C-11 and C-13 compared to the parent helenalin, reducing reactivity at that site while retaining the overall framework. This compound occurs alongside helenalin in flowers, often as ester forms such as dihydrohelenalin acetate. Semi-synthetic derivatives encompass conjugates like 2β-(S-)-2,3-dihydrohelenalin, formed via Michael-type addition of 's group to the α,β-unsaturated carbonyl in the dihydrohelenalin , resulting in a more polar at the 2β position. Additionally, helenalin esters, such as the , involve at the hydroxyl group at C-4, with chain lengths varying from short () to longer (tiglate or isovalerate). Structural modifications like esterification at hydroxyl sites generally increase , enhancing membrane permeability, while hydrogenation of double bonds, as in dihydrohelenalin, decreases electrophilic reactivity. Regarding , shorter ester chains (e.g., and isobutyrate) exhibit higher than helenalin itself in cell lines like L1210 cells, whereas longer chains (e.g., tiglate) reduce , likely due to steric hindrance and altered . However, comprehensive data remain limited for many derivatives, particularly regarding long-term effects and specific organ impacts beyond sensitization potential.

Biological Sources and Biosynthesis

Natural Occurrence

Helenalin, a sesquiterpene lactone, occurs naturally primarily in species of the genus Arnica and Helenium within the Asteraceae family, with significant concentrations found in Arnica montana (European arnica), Arnica chamissonis (meadow arnica), and various Helenium species such as H. autumnale. These plants are perennial herbs native to temperate regions, where A. montana inhabits nutrient-poor, acidic grasslands and meadows in mountainous areas of Europe, often at elevations between 600 and 2,500 meters, while A. chamissonis grows in similar open, moist meadows across North America. Helenium species are native to North America, with helenalin content reaching 0.5–3% dry weight in flowers. Within these plants, helenalin concentrations are highest in the flower heads, ranging from 0.2% to 1% of dry weight for helenalin and its derivatives in , whereas rhizomes and roots contain only trace amounts or none at all. In , levels are higher, up to 3% dry weight. The compound's levels vary significantly by plant part and are influenced by ecological parameters, including soil composition (e.g., siliceous versus substrates), altitude, , and . For example, studies have shown a positive between higher altitudes and elevated helenalin content in A. montana, likely due to stress responses in harsher environments. Helenalin is typically isolated from the flowers of and species using solvent extraction methods, such as with or other organic solvents, to yield the for further analysis or use. As a , it contributes to the plant's against herbivores and pathogens.

Biosynthesis

Helenalin, a pseudoguaianolide , is biosynthesized in such as from (FPP), which is produced via the mevalonate (MVA) pathway in the or the 2-C-methyl-D-erythritol-4-phosphate () pathway in plastids. FPP is formed by the condensation of (DMAPP) and isopentenyl diphosphate (IPP) catalyzed by farnesyl diphosphate (FDS). This precursor undergoes cyclization by synthases (STPSs), such as germacrene A (GAS), to form a germacrane precursor, which serves as the foundational for pseudoguaianolides like helenalin. Subsequent rearrangements lead to the characteristic pseudoguaianolide framework. Key biosynthetic steps include the initial cyclization of FPP to germacrene A, followed by oxidation via germacrene A (GAO, a from the CYP71A2-8 family) to introduce hydroxyl groups and facilitate ring modifications. Further oxidations and hydroxylations by enzymes from the CYP71BL subfamily form the α-methylene-γ- ring, while additional modifications by alcohol dehydrogenases, reductases, and acyltransferases introduce the exocyclic methylene and ester functionalities typical of helenalin derivatives. The introduction of the exocyclic methylene occurs through oxidative processes that activate the for . Although partial involvement of germacrene synthase has been identified, the full enzymatic sequence for helenalin remains unelucidated. Biosynthesis is localized primarily in the flower heads of Arnica species, with high concentrations in glandular trichomes of the corolla, pappus calyx, and ovary, where sesquiterpene lactones colocalize with inulin storage vacuoles. Content increases progressively from flower buds to full maturity, reflecting developmental regulation. Regulation of helenalin production is elicited by biotic and abiotic factors, including jasmonic acid (JA) at concentrations of 0.25–1 mg/L, which boosts sesquiterpene lactone yields by up to 66% in tissue cultures via JAZ-MYC signaling pathways; chitosan at 50–100 mg/L, increasing levels fivefold and favoring helenalin esters; and red light at 30–150 µmol m⁻² s⁻¹, enhancing accumulation by 60–300%. Recent studies from 2020–2025 demonstrate that these elicitors and stress conditions, such as low light or pathogen exposure, upregulate helenalin derivatives, promoting protective responses in young tissues and shifting metabolic profiles toward pseudoguaianolides under environmental stress.

Pharmacological Effects

Anti-inflammatory Effects

Helenalin demonstrates potent anti-inflammatory activity primarily through targeted inhibition of key signaling pathways in inflammatory cells. A primary mechanism involves the covalent of the , which orchestrates the expression of numerous pro-inflammatory genes. Helenalin alkylates residues, potentially including Cys38, on the p65 () subunit via Michael-type addition, thereby preventing NF-κB's DNA binding and subsequent activation of production, including tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). This NF-κB inhibition occurs downstream of IκB degradation and nuclear translocation, effectively blocking NF-κB-driven transcription in response to diverse stimuli such as TNF-α or phorbol esters. In vitro studies across cell models, including T-cells, B-cells, epithelial cells, and macrophages, show reduced inflammatory responses, with IC50 values for p65 DNA binding inhibition ranging from 2.5 to 5 μM in electromobility shift and surface plasmon resonance assays. Helenalin also suppresses the 5-lipoxygenase (5-LOX) pathway by alkylating groups on enzymes involved in biosynthesis. In polymorphonuclear granulocytes and platelets, it inhibits 5-LOX activity (IC50 ≈ 9 μM after 60-minute preincubation) and C4 synthase (IC50 ≈ 12 μM), thereby curtailing the production of pro-inflammatory that contribute to conditions like and allergic responses. This dual action on and 5-LOX pathways underscores helenalin's broad potential to dampen acute at multiple levels. Although helenalin's thiol reactivity underpins these effects, as detailed in its chemical properties, in vivo and clinical evidence remains limited, with studies confined largely to models. Preliminary indications suggest potential for topical application in models, where localized delivery could exploit its potency while minimizing systemic toxicity.

Anti-neoplastic Effects

Helenalin exhibits anti-neoplastic effects primarily through inhibition of and induction of in cancer cells. It alkylates the catalytic subunit of , thereby reducing human (hTERT) activity and expression, which limits the proliferative capacity of tumor cells. For instance, in the T47D cell line, helenalin significantly downregulated hTERT gene expression in a dose-dependent manner, with significant inhibition observed at 5 μM after of . This has also been demonstrated in hematopoietic cancer cells, where helenalin potently suppressed activity by directly interacting with the enzyme's residues. In addition to telomerase inhibition, helenalin promotes in various types via blockade of signaling—sharing this pathway with its anti-inflammatory actions—and by generating (ROS). The inhibition disrupts prosurvival pathways, sensitizing cells to death signals even in cases of Bcl-2 overexpression, as seen in human leukemic . Concurrently, helenalin elevates intracellular ROS levels, which trigger mitochondrial dysfunction and activation; ROS scavengers like N-acetylcysteine attenuated this in , confirming the dependency. In cells (DU145 and PC-3 lines), helenalin further targeted 1 (TrxR1), amplifying ROS-mediated and cell cycle arrest at G2/M phase, with effects prominent at 5-10 μM concentrations. Helenalin demonstrates in vitro cytotoxicity against multiple cancer cell lines, including those from leukemia (e.g., HL-60, Tmolt3), breast (e.g., T47D), and prostate (e.g., DU145), with IC50 values typically ranging from 0.5 to 10 μM. This potency arises from its ability to selectively target rapidly dividing cancer cells over normal ones, potentially extending to cancer stem cells due to its disruption of key survival pathways common in these populations. Derivatives such as helenalin acetate exhibit enhanced potency and improved solubility compared to the parent compound, facilitating better cellular uptake and stronger inhibition of transcription factors like C/EBPβ in tumor cells. As of 2025, helenalin's anti-neoplastic effects remain confined to preclinical studies, with no ongoing or completed clinical trials reported for cancer treatment.

Other Effects

Helenalin exhibits anti-trypanosomal activity by inhibiting key parasite enzymes through its reactivity with thiol groups, with in vitro IC50 values below 10 μM against Trypanosoma species; specifically, it shows an IC50 of 0.051 μM against T. brucei rhodesiense and 0.695 μM against T. cruzi. Similarly, helenalin demonstrates anti-malarial effects against the asexual blood stages of Plasmodium falciparum, with helenalin and related pseudoguaianolide sesquiterpene lactones displaying potent in vitro activity. Regarding antimicrobial properties, helenalin reduces growth in vitro within bovine mammary epithelial cells and limits bacterial proliferation in vivo in mouse models of mammary gland infection, leading to significantly fewer recoverable bacteria without causing host cell apoptosis. Helenalin also possesses immunosuppressive effects, suppressing essential functions of activated CD4+ T cells, including cytokine production and proliferation, positioning it as a candidate for treating T cell-mediated immune disorders. In terms of enzyme inhibition, helenalin partially inhibits human enzymes, particularly and , during its in liver microsomes, with inhibitory effects observed at micromolar concentrations.

Metabolism and Toxicity

Metabolism

Helenalin undergoes phase I primarily through enzymes in hepatic microsomes, with and identified as the main isoforms responsible in humans, alongside and extrahepatic CYP2A13. This process yields oxidative metabolites such as 14-hydroxyhelenalin in human liver microsomes and 9-hydroxyhelenalin in rat microsomes, along with reduced metabolites in cytosolic fractions. Notably, helenalin acts as a mechanism-based inhibitor of these enzymes, particularly (IC50 = 18.7 µM) and (IC50 = 62.6 µM), which may impair the of co-administered xenobiotics. In phase II metabolism, helenalin readily undergoes conjugation with (GSH) via (GST) enzymes, forming adducts such as the 2β-(S-glutathionyl)helenalin through Michael addition at the α-methylene-γ-lactone moiety. This reaction, which can occur spontaneously or enzymatically (as demonstrated with horse liver ), depletes intracellular GSH levels and contributes to the compound's electrophilic reactivity in biological systems. Although catalysis does not significantly accelerate the conjugation compared to non-enzymatic pathways, the resulting adducts inhibit activity, potentially exacerbating . In vitro studies using , pig, and liver microsomes have elucidated the of helenalin derivatives like helenalin and 11α,13-dihydrohelenalin , revealing predominant thiolation via GSH and conjugation (yielding up to four mono- and di-GSH adducts for helenalin ), alongside phase I hydroxylations but no detectable . These pathways highlight species-specific differences, with microsomes showing higher metabolic efficiency than ones. Additionally, acute exposure in rodents elevates liver enzymes such as ALT, indicating rapid hepatic impact during metabolism. Extensive liver conjugation suggests potential biliary and renal excretion routes, consistent with glutathione-mediated metabolism observed in related sesquiterpene lactones.

Toxicity

Helenalin exhibits significant acute toxicity via oral administration, with an LD50 ranging from 85 to 105 mg/kg in rodents such as mice and rats. This exposure leads to symptoms including gastroenteritis characterized by vomiting and diarrhea, progressive paralysis, and damage to hepatic and renal tissues, as evidenced by elevated serum markers like alanine aminotransferase and blood urea nitrogen. Topical application of helenalin can induce in sensitive individuals at concentrations exceeding 10%, manifesting as redness, itching, and eczematous reactions. However, formulations at or below 10% in gels are generally considered safe for external use, with low incidence of adverse skin effects when applied to intact skin. Chronic exposure to helenalin results in damage to lymphatic tissues, including reduced and weights, alongside that increases susceptibility to infections due to decreased counts. The primary mechanisms underlying this toxicity involve depletion of (GSH) through conjugation, leading to protein via Michael addition to residues and subsequent . This GSH depletion is exacerbated by metabolic conjugation processes. Human cases of helenalin are rare and typically arise from misuse of Arnica-containing products, such as internal , resulting in gastrointestinal distress and . No fatalities have been reported from helenalin exposure after , reflecting improved awareness and restricted use. Regulatory bodies have imposed strict limits on helenalin due to its profile; it is not approved by the FDA for internal use, classified as unsafe for . The () permits its presence in herbal products only for external application, with defined limits on content to minimize risks.

Applications

Historical Uses

Helenalin, a sesquiterpene lactone primarily found in plants of the genus Arnica, particularly Arnica montana, has been utilized in traditional medicine through the application of these plants for centuries. In European folk medicine, Arnica montana was employed topically to treat sprains, bruises, and rheumatism, with records dating back to the medieval period and continuing into the 18th century. Native American communities also incorporated various Arnica species, such as Arnica cordifolia, into their healing practices for similar purposes, including the treatment of trauma, cuts, bruises, and sore throats. By the , preparations gained formal recognition in pharmacopeias across and , where diluted tinctures were introduced in homeopathic medicine for relief associated with injuries and . These homeopathic formulations, often highly diluted to minimize risks, were applied externally or taken orally in low doses to alleviate muscle and . Helenalin was first isolated in 1949 from the flowers of . It was subsequently identified in Arnica montana flowers during the mid-20th century, marking a shift toward scientific investigation of its active components. Initial studies in the 1960s explored its anti-inflammatory potential, building on the empirical uses of extracts. However, concerns over toxicity led to the abandonment of oral Arnica use by the mid-20th century, restricting applications to topical forms to avoid adverse effects like and cardiac issues.

Modern Applications

In modern applications, helenalin is primarily utilized in topical formulations derived from extracts, such as gels and creams, for the symptomatic relief of muscle and pain, bruises, and associated with blunt injuries. These products typically contain low concentrations of lactones, including helenalin at levels of 0.3–1.0% in the herbal substance, ensuring external use only to minimize toxicity risks. Homeopathic preparations incorporating helenalin are commonly available in for similar indications, including rheumatic complaints and post-traumatic swelling. Ongoing preclinical explores helenalin's potential as an adjunct in , particularly for its anti-neoplastic effects in cell lines like T47D , where it inhibits and promotes . As of 2025, no clinical trials investigating helenalin for are registered, limiting its advancement to therapeutic use. To address helenalin's poor aqueous , nanoparticle-based delivery systems, such as nano-encapsulated forms and β-cyclodextrin complexes, have been developed in laboratory settings to enhance and targeted efficacy against tumor cells. The European Medicines Agency (EMA) permits low-dose herbal preparations of Arnica montana containing helenalin for traditional topical use under well-established or traditional registration, but systemic administration remains unapproved due to toxicity concerns. Challenges in broader application stem from helenalin's hepatotoxic and allergenic profile, prompting studies on derivatives like esters to potentially reduce toxicity while retaining bioactivity; for instance, certain acyl esters exhibit lower cytotoxicity in vitro compared to the parent compound. Future developments may include helenalin in anti-malarial combinations, given its demonstrated in vitro activity against Plasmodium falciparum blood stages at micromolar concentrations.

References

  1. [1]
    Helenalin - A Sesquiterpene Lactone with Multidirectional Activity
    Helenalin, an active component of Arnica montana, known for its strong anti-inflammatory activity, has been used for centuries in folk medicine to treat minor ...
  2. [2]
    Helenalin - an overview | ScienceDirect Topics
    Helenalin A is a constituent of Arnica montana with NF-κB inhibitory properties. Helenalin inhibits the binding of the NF-κB complex with DNA and alkylates the ...
  3. [3]
  4. [4]
    The Anti-inflammatory Sesquiterpene Lactone Helenalin Inhibits the ...
    The sesquiterpene lactone helenalin is a potent anti-inflammatory drug whose molecular mechanism of action remains unclear despite numerous investigations.
  5. [5]
    Helenalin | C15H18O4 | CID 23205 - PubChem - NIH
    It has a role as an anti-inflammatory agent, an antineoplastic agent, a plant metabolite and a metabolite. It is a gamma-lactone, a cyclic ketone, an organic ...
  6. [6]
    Helenalin | C15H18O4 - ChemSpider
    [IUPAC name – generated by ACD/Name]. (3aS,4S,4aR,7aR,8R,9aR)-4-Hydroxy-4a,8-dimethyl-3-methylene-3,3a,4,4a,7a,8,9,9a-octahydroazuleno[6,5-b]furan-2,5-dione.
  7. [7]
    Helenalin - an overview | ScienceDirect Topics
    Helenalin is defined as a sesquiterpene lactone that exists in polymorphic forms, which differ primarily in their hydrogen-bonding patterns and packing modes ...
  8. [8]
    Helenalin Analogues Targeting NF-κB p65: Thiol Reactivity ... - NIH
    Helenalin contains two Michael acceptors that covalently modify cysteines, a α-methylene-γ-butyrolactone and a cyclopentenone. We recently reported two ...
  9. [9]
    Electrophilic reactivities of cyclic enones and α,β-unsaturated lactones
    Feb 9, 2021 · GSH was reported to attack faster, yet reversible, at the cyclopentenone moiety of helenalin than at the α-methylene butyrolactone part.
  10. [10]
    Targeting NF-κB p65 with a Helenalin Inspired Bis-electrophile - PMC
    Reduction of both Michael acceptors on helenalin ablates all activity. The cyclopentenone and α-methylene-γ-butyrolactone of helenalin can engage ...
  11. [11]
    Phosphine-Catalyzed Michael Additions to α-Methylene-γ ...
    Helenalin contains two Michael acceptors that covalently modify cysteines: a α-methylene-γ-butyrolactone and a cyclopentenone. We recently reported two ...<|control11|><|separator|>
  12. [12]
    Structure-cytotoxicity relationships of some helenanolide ... - PubMed
    The results may be interpreted in terms of lipophilicity and steric effects on the accessibility of the reactive sites considered responsible for biological ...
  13. [13]
    Quantitative Structure−Activity Relationship of Sesquiterpene ...
    They concluded, that the existence of an α-methylene-γ-lactone moiety is essential for their cytotoxic activity and that an α,β-unsaturated ester or ...
  14. [14]
  15. [15]
  16. [16]
    Helenalin - A Sesquiterpene Lactone with Multidirectional Activity
    Aug 10, 2025 · Unfortunately, helenalin's ability to cause allergic reactions and its toxicity to healthy tissues prevented so far the development of this ...Missing: esterification | Show results with:esterification
  17. [17]
    Helenalin, an anti-inflammatory sesquiterpene lactone from Arnica ...
    Helenalin, from Arnica, is an anti-inflammatory that inhibits NF-kappaB by modifying the NF-kappaB/IkappaB complex, preventing IkappaB release.
  18. [18]
    Habitat specific threats to Arnica montana L. populations in Hesse ...
    May 29, 2020 · Populations of Arnica montana, a characteristic species of nutrient poor grasslands in Central Europe, have been deteriorating over the last decades, ...
  19. [19]
    Soil and Vegetation Drive Sesquiterpene Lactone Content and ...
    Jan 27, 2022 · The findings of this study shed light upon the often ignored, complex interactions between environmental conditions and plant secondary metabolites.
  20. [20]
    Arnica montana L.: Doesn't Origin Matter? - MDPI
    Oct 11, 2023 · Arnica montana L. (Asteraceae) is a medicinal plant species that has been used for many centuries in European medicine. From the Middle Ages ...
  21. [21]
    Localization of Sesquiterpene Lactones Biosynthesis in Flowers of ...
    May 27, 2023 · Arnica montana is a valuable plant with high demand on the pharmaceutical and cosmetic market due to the presence of helenalin (H) and 11α, 13- ...
  22. [22]
  23. [23]
    Variation of Sesquiterpene Lactone Contents in Different Arnica ...
    Aug 7, 2025 · The SL content can be influenced by genetic factors and environmental conditions (altitude, temperature and rainfall). ... environmental factors ...
  24. [24]
    Soil and Vegetation Drive Sesquiterpene Lactone Content and ...
    Jan 28, 2022 · The SL content can be influenced by genetic factors and environmental conditions (altitude, temperature and rainfall).
  25. [25]
    (PDF) Sesquiterpene Lactones in Arnica montana: Helenalin and ...
    Statistical analyses reveal altitude negatively correlates with dihydrohelenalin levels and positively correlates with helenalin levels. ... levels in A. montana ...
  26. [26]
  27. [27]
    Buy Helenalin (EVT-269430) | 6754-13-8 - EvitaChem
    The compound features a unique arrangement of rings and functional groups that contribute to its reactivity. Structure. Molecular Formula: C15H18O4; Key ...
  28. [28]
  29. [29]
  30. [30]
    (+)-Germacrene A Biosynthesis: The Committed Step in the ... - NIH
    It is assumed that both the guaiane- and eudesmane-type lactones originate from a common germacrane precursor that is formed via the acetate-mevalonate-FPP ...Missing: pseudoguaianolide helenalin
  31. [31]
    Surface plasmon resonance analysis of nuclear factor-kappaB ...
    Jun 1, 2010 · When DNA with NF-kappaB binding sites was immobilized on sensor chips, the binding of RelA was inhibited by helenalin with an IC(50) of 5.0 ...Missing: IC50 | Show results with:IC50
  32. [32]
    Cytotoxic versus anti-inflammatory effects in HeLa, jurkat t and ...
    The electromobility shift assay (EMSA), revealed a stronger inhibition of NF-κB for 1 (IC50 2.5 μM) than for 4 (IC50 5 μM). Both compounds were also subjected ...Missing: IC50 | Show results with:IC50
  33. [33]
    Inhibitory effects of helenalin and related compounds on 5 ... - PubMed
    In contrast, the drug was without effect on LTA(4) hydrolase. The GSH-containing adducts (2beta-(S-glutathionyl)-2,3-dihydrohelenalin and 2beta-(S-glutathionyl ...Missing: 2β | Show results with:2β
  34. [34]
    Potential Anti-Cancer Effect of Helenalin as a Natural Bioactive ...
    In this study, we investigated the inhibitory effect of helenalin extract on telomerase gene expression in the T47D breast cancer cell line.
  35. [35]
    Potent inhibition of human telomerase by helenalin - PubMed
    Furthermore, we demonstrated that helenalin can inhibit the expression of hTERT and telomerase in hematopoietic cancer cells. Therefore, the anti-tumor activity ...
  36. [36]
    Helenalin bypasses Bcl-2-mediated cell death resistance by ...
    Sep 1, 2011 · Our results highlight the NF-κB inhibitor helenalin as a promising chemotherapeutic agent to overcome Bcl-2-induced cell death resistance.
  37. [37]
    Helenalin-induced apoptosis is dependent on production of reactive ...
    Helenalin markedly increased intracellular ROS levels, and ROS scavengers inhibited helenalin-induced apoptosis. ... Helenalin suppresses NF-κB DNA binding and ...
  38. [38]
    Helenalin Facilitates Reactive Oxygen Species-Mediated Apoptosis ...
    Our findings revealed that helenalin accelerated ROS-mediated apoptosis and cell cycle arrest via targeting TrxR1 in human prostate cancer cells.Material And Methods · Apoptosis Assay · Figure 3<|control11|><|separator|>
  39. [39]
    Decreased helenalin-induced cytotoxicity by flavonoids from Arnica ...
    Helenalin concentrations around its control IC50 value, 0.5 μM, were combined with flavonoid concentrations ranging from 0.01 to 20 μM. At non-toxic ...Missing: IC50 | Show results with:IC50
  40. [40]
    (PDF) The cytotoxicity of helenalin, its mono and difunctional esters ...
    Aug 5, 2025 · Helenalin and its esters were highly cytotoxic against several cancer cell lines (murine L1210 and human Tmolt3 leukemia, epidermoid ...
  41. [41]
    Helenalin Acetate, a Natural Sesquiterpene Lactone with Anti ... - NIH
    Helenalin and its acetate ester helenalin acetate have anti-inflammatory activities and were previously shown to inhibit the transcription factor NF-κB, a key ...
  42. [42]
    Recent Patents on Anti-Cancer Potential of Helenalin
    May 1, 2020 · Conclusion: The promising anti-cancer potential of helenalin in various preclinical studies may open new avenues for therapeutic interventions ...
  43. [43]
    Anti-trypanosomal activity of helenalin and some structurally related ...
    Helenalin was the most active compound in the series with IC50 values of 0.051 and 0.695 microM against T. brucei rhodesiense and T. cruzi, respectively. The ...
  44. [44]
    Pseudoguaianolide sesquiterpene lactones with high activities ...
    Four sesquiterpene lactones of the pseudo-guaianolide type (helenalin, dihydrohelenalin and their acetates), have shown activities against asexual blood ...Missing: anti- | Show results with:anti-
  45. [45]
    Helenalin reduces Staphylococcus aureus infection in vitro and in vivo
    Helenalin reduces Staphylococcus aureus infection in vitro and in vivo. Vet ... Helenalin is a sesquiterpene lactone with potent anti-inflammatory properties.
  46. [46]
    Antimicrobial Activity of Lactones - PMC - PubMed Central - NIH
    Sep 29, 2022 · Helenalin—A ... Inhibition of Quorum Sensing-Controlled Biofilm Formation in Pseudomonas Aeruginosa by Quorum-Sensing Inhibitors.
  47. [47]
    Helenalin suppresses essential immune functions of activated CD4+ ...
    Helenalin is a naturally occuring sesquiterpene lactone extracted from Arnica montana and Arnica chamissonis ssp. foliosa. Helenalin and its derivatives are ...Missing: biosynthesis | Show results with:biosynthesis
  48. [48]
    In vitro metabolism of helenalin and its inhibitory effect on human ...
    Jan 6, 2022 · The overall oxidation of helenalin was several times more efficient in rat than in human liver microsomes. In humans, CYP3A4 and CYP3A5 followed ...<|control11|><|separator|>
  49. [49]
  50. [50]
    Acute Toxicity of Helenalin in BDF1 Mice - ResearchGate
    Aug 7, 2025 · Cholesterol synthesis was also inhibited, resulting in lower serum cholesterol levels in tumor-bearing animals. Data obtained in vitro ...
  51. [51]
    Mammalian toxicity of helenalin, the toxic principle of Helenium ...
    The oral median lethal dose of helenalin for 5 mammalian species was between 85 and 105 mg/kg. MeSH terms. Animals; Cricetinae; Lactones / toxicity*; Mice ...
  52. [52]
    Range Plants of Temperate North America - Toxicology
    Anorexia, severe gastroenteritis, salivation, diarrhea, paralysis, photosensitization, hemoglobinuria. Unknown toxic principle in B incana causes rapid ...
  53. [53]
    [PDF] Assessment report on Arnica montana L., flos
    May 6, 2014 · Topical 20% Arnica ointment may be able to reduce bruising more than low-concentration vitamin K formulations. 4 patients reported redness and ...<|control11|><|separator|>
  54. [54]
    Treatment of viral infections and virally associated lesions with ...
    ... 2β-(S-glutathionyl)-2,3-dihydrohelenalin. In general, most derivatives are more toxic than H. tox itself. Among these, derivatives with the shortest ester ...
  55. [55]
    Role of glutathione in the toxicity of the sesquiterpene lactones ...
    These studies suggest that the in vivo and in vitro toxicity of hymenoxon and helenalin is strongly dependent on hepatic glutathione levels, which hymenoxon and ...Missing: GSH protein
  56. [56]
  57. [57]
    Final Report on the Safety Assessment of Arnica Montana Extract ...
    Ingestion of A. montana–containing products has induced severe gastroenteritis, nervousness, accelerated heart rate, muscular weakness, and death. Absent any ...
  58. [58]
    Arnica Uses, Benefits & Dosage - Drugs.com
    May 8, 2025 · Arnica irritates mucous membranes and causes stomach pain, diarrhea, and vomiting. Allergy and contact dermatitis have been reported. Toxicology.
  59. [59]
    Arnica | Herbs - Herbal Reality
    Feb 1, 2025 · Arnica is largely used to treat bruises and sprains for this rubefacient (counter-irritant) action, bringing warmth to an area via the increased blood flow.
  60. [60]
    [PDF] Arnica - A.Vogel
    Vogel Rheumatism Gel possesses anti-inflammatory, antiseptic, antiphlogistic and blood-flow promoting properties. The anti-inflammatory action is based mainly.
  61. [61]
    Arnica for Pain: Clinical Trials, Mechanisms & Effects
    Oct 9, 2021 · In clinical trials, adverse dermatologic effects were commonly reported with topical therapies. Contact dermatitis can develop, resulting in a ...
  62. [62]
    Helenalin. I. Isolation and Properties - ACS Publications
    Untersuchungen über die Inhaltsstoffe von Arnica‐Arten, 9. Mitt. Zwei Sesquiterpenlactone aus den Blüten von Arnica longifolia. Archiv der Pharmazie 1976 ...
  63. [63]
    A comparison of the inhibitory effect of nano-encapsulated helenalin ...
    A recent study used the PLGA-PEG-helenalin complex, and free helenalin, to inhibit the expression of telomerase in the breast cancer cell line. The purpose of ...
  64. [64]
    Inhibitory effects of β-cyclodextrin-helenalin complexes on H-TERT ...
    Helenalin, with a hydrophobic structure obtained from flowers of Arnica chamissonis and Arnica Montana, has anti-cancer and anti-inflammatory activity but low ...